Save your place

Sign in to WhoBought

Please try again later.

Mereo BioPharma Group plc (MREO) institutional ownership

Latest close $0.30 Jul 27, 2026
Market cap$281M 52-week range SectorHealthcare
Funds holding · Q1 2026
67
reported MREO position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
30 buyers · 37 sellers

Mereo BioPharma Group plc (MREO) price and institutional activity

Dates

Q1 2026

$0 bought by 30 investors
Bank of America CorpDefilade Capital Management, L.P. +28 more
$0 sold by 37 investors
Schonfeld Strategic Advisors LLC683 Capital Management, LLC +35 more
Bought Sold Totals per quarter; hover a bar for the names.

Mereo BioPharma Group plc (MREO) institutional activity · 67

Investor Type Est. change Change Δ Own Date
Bank of America Corp · Added
Change +8.2M Date Q1 2026
Bank of America Corp Added· Q1 2026 +8.2M Q1 2026
Defilade Capital Management, L.P. · New
Change +7.6M Date Q1 2026
Defilade Capital Management, L.P. New· Q1 2026 +7.6M Q1 2026
Newtyn Management, LLC · Added
Change +6.9M Date Q1 2026
Newtyn Management, LLC Added· Q1 2026 +6.9M Q1 2026
Schonfeld Strategic Advisors LLC · Exited
Change −6.1M Δ Own −100.0% Date Q1 2026
Schonfeld Strategic Advisors LLC Exited· Q1 2026 −6.1M −100.0% Q1 2026
Ecor1 Capital, LLC · Added
Change +5.5M Date Q1 2026
Ecor1 Capital, LLC Added· Q1 2026 +5.5M Q1 2026
Millennium Management LLC · Added
Change +3.5M Date Q1 2026
Millennium Management LLC Added· Q1 2026 +3.5M Q1 2026
683 Capital Management, LLC · Reduced
Change −3.0M Date Q1 2026
683 Capital Management, LLC Reduced· Q1 2026 −3.0M Q1 2026
Logos Global Management LP · Exited
Change −1.9M Δ Own −100.0% Date Q1 2026
Logos Global Management LP Exited· Q1 2026 −1.9M −100.0% Q1 2026
UBS AM · Exited
Change −1.8M Δ Own −100.0% Date Q1 2026
UBS AM Exited· Q1 2026 −1.8M −100.0% Q1 2026
Monaco Asset Management Sam · Exited
Change −1.6M Δ Own −100.0% Date Q1 2026
Monaco Asset Management Sam Exited· Q1 2026 −1.6M −100.0% Q1 2026
Balyasny Asset Management L.P. · Exited
Change −1.3M Δ Own −100.0% Date Q1 2026
Balyasny Asset Management L.P. Exited· Q1 2026 −1.3M −100.0% Q1 2026
Morgan Stanley · Reduced
Change −1.3M Date Q1 2026
Morgan Stanley Reduced· Q1 2026 −1.3M Q1 2026
Wealthspire Advisors, LLC · New
Change +796K Date Q1 2026
Wealthspire Advisors, LLC New· Q1 2026 +796K Q1 2026
Marshall Wace, LLP · New
Change +687K Date Q1 2026
Marshall Wace, LLP New· Q1 2026 +687K Q1 2026
Simplex Trading, LLC · Exited
Change −419K Δ Own −100.0% Date Q1 2026
Simplex Trading, LLC Exited· Q1 2026 −419K −100.0% Q1 2026
Data through Q1 2026 · filed May 26, 2026
15 of 67

Famous investor activity in Mereo BioPharma Group plc (MREO)

Mereo BioPharma Group plc (MREO) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Jacquet Pierre · Director 2 operations 173K
Owned 66K Trade date Feb 26, 2026 Filed date Feb 27, 2026
Jacquet Pierre Director 2 operations 173K 66K Feb 26, 2026 Feb 27, 2026
Yoskowitz Marc J. · Director 2 operations 162K
Owned 66K Trade date Feb 26, 2026 Filed date Feb 27, 2026
Yoskowitz Marc J. Director 2 operations 162K 66K Feb 26, 2026 Feb 27, 2026
Shames Daniel · Director 2 operations 162K
Owned 96K Trade date Feb 26, 2026 Filed date Feb 27, 2026
Shames Daniel Director 2 operations 162K 96K Feb 26, 2026 Feb 27, 2026
Ekblom Anders · Director 2 operations 200K
Owned 134K Trade date Feb 26, 2026 Filed date Feb 27, 2026
Ekblom Anders Director 2 operations 200K 134K Feb 26, 2026 Feb 27, 2026
Bender Jeremy · Director 2 operations 184K
Owned 118K Trade date Feb 26, 2026 Filed date Feb 27, 2026
Bender Jeremy Director 2 operations 184K 118K Feb 26, 2026 Feb 27, 2026
Pakianathan Deepika · Director Grant (A) 66K
Owned 66K Trade date Feb 26, 2026 Filed date Feb 27, 2026
Pakianathan Deepika Director Grant (A) 66K 66K Feb 26, 2026 Feb 27, 2026
Jenkins Annalisa · Director 2 operations 173K
Owned 66K Trade date Feb 26, 2026 Filed date Feb 27, 2026
Jenkins Annalisa Director 2 operations 173K 66K Feb 26, 2026 Feb 27, 2026
Wyzga Michael S. · Director Grant (A) 66K
Owned 66K Trade date Feb 26, 2026 Filed date Feb 27, 2026
Wyzga Michael S. Director Grant (A) 66K 66K Feb 26, 2026 Feb 27, 2026
Lewicki John A. · Officer 3 operations 332K
Owned 145K Trade date Feb 1, 2026 Filed date Feb 2, 2026
Lewicki John A. Officer 3 operations 332K 145K Feb 1, 2026 Feb 2, 2026
Hughes-Wilson Alexandra · Officer 3 operations 440K
Owned 195K Trade date Feb 1, 2026 Filed date Feb 2, 2026
Hughes-Wilson Alexandra Officer 3 operations 440K 195K Feb 1, 2026 Feb 2, 2026
Sermon Charles · Officer 3 operations 716K
Owned 295K Trade date Feb 1, 2026 Filed date Feb 2, 2026
Sermon Charles Officer 3 operations 716K 295K Feb 1, 2026 Feb 2, 2026
Scots-Knight Denise · Director, Officer 3 operations 1.9M
Owned 480K Trade date Feb 1, 2026 Filed date Feb 2, 2026
Scots-Knight Denise Director, Officer 3 operations 1.9M 480K Feb 1, 2026 Feb 2, 2026
Fox Christine Ann · Officer 3 operations 701K
Owned 105K Trade date Feb 1, 2026 Filed date Feb 2, 2026
Fox Christine Ann Officer 3 operations 701K 105K Feb 1, 2026 Feb 2, 2026
13 of 13

Mereo BioPharma Group plc (MREO) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Rubric Capital Management LP 108.5M
% of shares outstanding 14.2% Filing date Jun 17, 2024
Rubric Capital Management LP 108.5M 14.2% Jun 17, 2024
Ecor1 Capital, LLC 66.8M
% of shares outstanding 8.4% Filing date May 15, 2026
Ecor1 Capital, LLC 66.8M 8.4% May 15, 2026
683 Capital Management, LLC 65.1M
% of shares outstanding 8.2% Filing date Jan 6, 2026
683 Capital Management, LLC 65.1M 8.2% Jan 6, 2026
Janus Henderson Group PLC 12.3M
% of shares outstanding 8.0% Filing date Nov 14, 2024
Janus Henderson Group PLC 12.3M 8.0% Nov 14, 2024
Adage Capital Management, L.P. 43.6M
% of shares outstanding 5.6% Filing date Feb 12, 2025
Adage Capital Management, L.P. 43.6M 5.6% Feb 12, 2025
Bank of America Corp 41.0M
% of shares outstanding 5.1% Filing date May 14, 2026
Bank of America Corp 41.0M 5.1% May 14, 2026
Mangrove Partners Im, LLC 39.0M
% of shares outstanding 4.9% Filing date Nov 14, 2025
Mangrove Partners Im, LLC 39.0M 4.9% Nov 14, 2025
Rock Springs Capital Management LP 33.4M
% of shares outstanding 4.2% Filing date May 15, 2025
Rock Springs Capital Management LP 33.4M 4.2% May 15, 2025
8 of 14

Mereo BioPharma Group plc (MREO) ownership FAQ

Who owns MREO?

67 reporting institutions disclosed MREO position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.